

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 March 2001 (22.03.2001)

PCT

(10) International Publication Number
WO 01/19998 A1

(51) International Patent Classification⁷: C12N 15/31,
15/09, 1/21, A61K 39/108 // (C12N 1/21, C12R 1:19)

Kyonggi-di 463-010 (KR). CHUNG, Soo-il [US/KR];
112-902, Hyundai Apt., Hyoja-chon, Seohyun-dong,
Pundang-ku, Sungnam-si, Kyonggi-do 463-480 (KR).

(21) International Application Number: PCT/KR99/00555

(74) Agent: LEE, Han-Young; Seowon Building, 8th floor,
1675-1, Seocho-dong, Seocho-gu, Seoul 137-070 (KR).

(22) International Filing Date:
15 September 1999 (15.09.1999)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US): MOGAM
BIOTECHNOLOGY RESEARCH INSTITUTE
[KR/KR]; 341, Pojung-ri, Koosung-myon, Yongin-si,
Kyonggi-do 449-910 (KR).

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE,
ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ,
VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PARK, Eun, Jeong
[KR/KR]; 322-1007, Woosung Apt., Sangrok-maeul,
Jungja-dong, Pundang-ku, Sungnam-si, Kyonggi-do
464-010 (KR). KIM, Jang, Seong [KR/KR]; 902 Ikjoo
Apt., Yeonmoo-dong, Jangan-ku, Suwon, Kyonggi-do
440-240 (KR). CHANG, Jihoon [KR/KR]; 553-517,
Jayang 3-dong, Kwangjin-ku, Seoul 143-193 (KR).
YUM, Jungsun [KR/KR]; 115-502, Chunggu Apt.,
Hansol-maeul, Jungja-dong, Pundang-ku, Sungnam-si,

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL DETOXIFIED MUTANTS OF *ESCHERICHIA COLI* HEAT-LABILE ENTEROTOXIN

(57) Abstract: The present invention relates to detoxified and immunologically active proteins ("mutant LTs") having mutated amino acid sequences of heat-labile enterotoxin of *E. coli*, DNA sequences encoding the mutant LTs, recombinant expression vectors comprising the DNAs, recombinant microorganisms transformed with the recombinant expression vectors, process for preparing the mutant LTs and pharmaceutical application of the said protein as immunogenic antigens for vaccination and as adjuvants for antibody production. In contrast to wild-type LT, the mutant LTs did not induce any toxic activities. The mutant LTs elicited high and comparable levels of anti-LT antibodies when delivered either intragastrically or intranasally, inducing systemic and local responses in serum and fecal extracts. Thus, they might be useful for the development of a novel diarrheal vaccine in humans and animals. In addition, the antibody production ability using mutant LTs as an adjuvant may be effective for prevention and treatment of various diseases.

**NOVEL DETOXIFIED MUTANTS OF
Escherichia coli HEAT-LABILE ENTEROTOXIN**

5 BACKGROUND OF THE INVENTION

Field of the Invention

10 The present invention relates to detoxified and immunologically active proteins("mutant LTs"), more specifically, to mutant LTs having mutated amino acid sequences of heat-labile enterotoxin of *E. coli*, DNA sequences encoding the mutant LTs, recombinant expression vectors comprising the DNAs, recombinant microorganisms
15 transformed with the recombinant expression vectors, process for preparing the mutant LTs and pharmaceutical application of the said proteins as immunogenic antigens for vaccination and as adjuvants for antibody production.

20 Description of the Prior Art

Enterotoxigenic *Escherichia coli*("ETEC") strain causes diarrheal disease in humans and animals due to production of toxin such as heat-labile
25 enterotoxin("LT")(see: Spangler, B.D., Microbiol. Rev., 56:622-647(1992)). LT is a multimeric protein composed of two functionally distinct domains: an enzymatically active A subunit("LTA") of ~30,000daltons with ADP-ribosylating activity, and a pentameric B subunit("LTB") of
30 ~11,600daltons that contains GM1(monosialoganglioside) receptor-binding site(see: Bäckström, M. et al., Mol. Microbiol., 24:489-497(1997)). Upon thiol reduction, the A subunit dissociates into two polypeptide chains, i.e., A1(Mr, 23,000 daltons) and A2(Mr, 6,000daltons)(see: Tsuji, T. et al., J. Biol. Chem., 260:8552-8558(1985); Grant C.C.R.
35 et al., Infect. Immun., 62:4270-4278(1994)). The A1 subunit, in particular, intoxicates eucaryotic cells by

catalyzing ADP-ribosylation of Gs, a GTP-binding protein that regulates the levels of the second messenger cAMP(see: Guerrant, R.L. et al., Infect. Immun., 10:320-327(1974); Field, M. et al., N. Engl. J. Med., 321:800-806(1989)).

5 The resulting increase in cAMP level causes secretion of water and electrolytes into the small intestine through interaction with two cAMP-sensitive ion transport mechanisms including (i) NaCl co-transport across the brush border of villous epithelial cells and (ii) electrogenic
10 Na⁺-dependent Cl⁻ secretion by crypt cells(see: Guidry, J.J. et al., Infect. Immun., 65:4943-4950(1997)).

Both the cholera toxin("CT") from *Vibrio cholerae* and heat-labile enterotoxin from ETEC belong to the most potent mucosal adjuvants and immunogens known to date by oral and
15 other mucosal routes, via which most of antigens are unable to induce immune responses(see: Jackson, R.J. et al., Infect. Immun., 61:4272-4279(1993); Takahashi, I. et al., J. Infect. Dis., 173:627-635(1996)). However, their toxicities have precluded their clinical use in humans(see: Douce, G.
20 et al., Proc. Natl. Acad. Sci., USA, 92:1644-1648(1995)). One approach to overcome the problem of toxicity is the generation of genetically detoxified derivatives of LT(see: Lobet, Y. et al., Infect. Immun., 59:2870-2879(1991); Dickson, B.L. and Clements, J.D., Infect. Immun., 63:1617-
25 1623(1995)) and CT(see: Fontana, M.R. et al., Infect. Immun., 63:2356-2360(1995); Yamamoto, S. et al., Proc. Natl. Acad. Sci., USA, 94:5267-5272(1997b)) by site-directed mutagenesis of amino acids which are located on the β -strand that constitutes the 'floor' of NAD-binding cavity.

30 The most important factor for immunogenicity is shown to be the ability to bind to the receptor on eucaryotic cell(see: Nashar, T.O. et al., Proc. Natl. Acad. Sci., USA, 93:226-230(1996)). In fact, a non-binding mutant of the B subunit of LT was found to be non-immunogenic(see: Guidry, J.J. et al., Infect. Immun., 65:4943-4950(1997)).
35 In addition, another group found that the ADP-ribosylating activity is unnecessary for immunogenicity because nontoxic

derivatives of LT obtained by site-directed mutagenesis of the A subunit retained the immunological properties of the wild-type LT(see: Pizza, M. et al., J. Exp. Med., 180:2147-2153(1994)).

5 The attempt to define the role of ADP-ribosylating activity in adjuvanticity of LT has generated conflicting results. For example, it was reported that a nontoxic derivative of LT(LTE112K) when co-administered with keyhole limpet hemocyanin(KLH) by an oral route in mice, lacked the
10 adjuvant properties, thus suggesting that the adjuvanticity of LT is linked to its ADP-ribosylating activity(see: Lycke, N. et al., Eur. J. Immunol., 22:2277-2281(1992)). However, more recently, the adjuvant activity of the LTE112K was found to be identical to that of the LT holotoxin when
15 delivered with influenza virus surface antigen by an intranasal route(see: Verweij, W.R et al., Vaccine, 16:2069-2076(1998)). On the other hand, other investigators showed that another LT derivatives, LTK63, lacking enzymatic activity and toxicity was still able to elicit
20 antibody responses against the co-administered antigen in mice immunized orally, intranasally, or intravaginally(see: Di Tommaso, A. et al., Infect. Immun., 64:974-979(1996); Giuliani, M.M. et al., J. Exp. Med., 187:1123-1132(1998); Marchetti, M. et al., Vaccine, 16:33-37(1998)).

25 Under the circumstances, the present inventors, based on the findings that detoxified LT derivatives may induce antibody responses, tried to explore an efficient immunogenic antigen and mucosal adjuvant for vaccination, which can be applied for the development of a mucosal
30 vaccine as well as a novel diarrheal vaccine for humans and animals.

SUMMARY OF THE INVENTION

35 In accordance with the present invention, the inventors have made an effort to develop detoxified and immunologically active proteins("mutant LTs") by the site-

directed mutagenesis of heat-labile enterotoxin(LT) of *E. coli*. The inventors cloned full length DNA coding for the LT, mutated the A subunit by site-directed mutagenesis and constructed expression vectors comprising the DNAs of mutated LT and recombinant microorganisms transformed with the recombinant expression vectors. Further, the inventors found that the recombinant mutant LTs can be applied as an active ingredient for diarrheal vaccine and adjuvant for mucosal vaccine.

The first object of the invention is, therefore, to provide detoxified and immunologically active proteins which have mutated amino acid sequences of heat-labile enterotoxin of *E. coli*.

The second object of the invention is to provide DNA sequences encoding the said mutant LTs.

The third object of the invention is to provide recombinant expression vectors comprising the said DNAs.

The fourth object of the invention is to provide recombinant microorganisms transformed with the said recombinant expression vectors.

The fifth object of the invention is to provide a process for preparing recombinant mutant LTs from the said microorganisms.

The sixth object of the invention is to provide a diarrheal vaccine comprising an active ingredient of mutant LT.

The seventh object of the invention is to provide a novel use of the mutant LT as an adjuvant for mucosal vaccine.

BRIEF DESCRIPTION OF THE INVENTION

The above and the other objects and features of the present invention will become apparent from the following description given in conjunction with the accompanying drawings, in which:

Figure 1 is a photograph showing SDS-PAGE of a wild-type and mutant LTs produced and isolated from recombinant *E. coli*.

Figure 2 is photographs showing the changes in CHO-K1 cell morphology after treatment with wild-type or mutant LTs.

Figure 3 is a photograph showing ADP-ribosyltransferase activity of wild-type LT, LTS63Y and LTΔ110/112 analyzed by SDS-PAGE followed by autoradiography.

Figure 4 is a graph showing the amount of intracellular cAMP of CHO cells measured by an enzyme immunoassay system after treatment with wild-type or mutant LTs.

Figure 5 is graphs showing anti-LT secretory IgA, serum IgG and IgA antibody responses on intragastric or intranasal immunization.

Figure 6 is graphs showing anti-urease secretory IgA, serum IgG and IgA antibody responses on intragastric immunization.

Figure 7 is graphs showing anti-urease secretory IgA, serum IgG and IgA antibody responses on intranasal immunization.

Figure 8A is a graph showing anti-urease serum IgG subclass antibody responses on intragastric immunization.

Figure 8B is a graph showing anti-urease serum IgG subclass antibody responses on intranasal immunization.

5 DETAILED DESCRIPTION OF THE INVENTION

The present inventors first isolated a DNA fragment including heat-labile enterotoxin(LT) gene from enterotoxigenic *E. coli* K88ac strain of porcine origin and
10 thus cloned into pBluescript KS(-) vector to generate pBlueKS-/rLT for site-directed mutagenesis. Site-directed mutagenesis was performed on single-stranded DNA of pBlueKS-/rLT vector. As a result, two vectors that have mutated DNA sequences encoding amino acids of proposed ADP-
15 ribosyltransferase active center of LT were generated: the first one is 'pBlueKS-/LTS63Y' wherein serine residue at position 63 of LT is substituted with tyrosine; and, the other one is 'pBlueKS-/LT/110/112' wherein glutamic acid residues at positions 110 and 112 are deleted.

20 Amino acids at positions 58 to 72 are shown to be folded in a β -strand followed by α -helix, which form the NAD-binding site and amino acids Arg⁷, His⁴⁴, Ser⁶¹ Glu¹¹⁰ and Glu¹¹² have been shown to be important for enzymatic activity. Up to date, the modified residues of the LTA
25 subunit are Arg⁷, Ser⁶³, Glu¹¹⁰, Glu¹¹² or Ala⁷².

The inventors have substituted Ser⁶³, the essential amino acid for NAD-binding and catalytic activity of LT, with Tyr residue having a bulky side chain of phenolic ring. Thus, it was expected to efficiently block NAD-binding in
30 slightly modified LT structure. The inventors have also deleted Glu¹¹⁰ and Glu¹¹² in LTA subunit which are important for enzymatic activity, and have studied for immunogenicity to LT itself and immune-eliciting property against coadministered antigens. The double deletion mutant of the
35 invention was expected to completely eliminate enzymatic activity of LT.

In describing the mutant LTs of the present invention, LTS63Y is employed to mean mutated LT in which serine residue at position 63 is substituted with tyrosine; and, "LT Δ 110/112" is employed to mean mutated LT in which glutamic acid residues at positions 110 and 112 of LT are deleted, respectively.

pBlueKS-/LTS63Y and pBlueKS-/LT Δ 110/112, were transformed into *E. coli* Top 10F'. Each of the transformants thus prepared was designated as '*Escherichia coli* Top 10F'-pBlueKS-/LTS63Y' and '*Escherichia coli* Top 10F'-pBlueKS-/LT Δ 110/112' and deposited with the Korean Collection for Type Cultures(KCTC) located at KRIBB #52, Oun-dong, Yusong-gu, Taejon 305-333, Republic of Korea, an international depository authority as accession Nos. KCTC 0648BP and KCTC 0649BP, respectively.

E. coli Top 10F' transformed with either pBlueKS-/LTS63Y or pBlueKS-/LT Δ 110/112 was grown in LB broth containing 100 μ g/ml of ampicillin and the mutant LTs were purified from the cultures using immobilized D-galactose column and FPLC Superdex 200 column.

Since the mobilities of mutant LTs were identical to those of the wild-type LT on SDS-PAGE analysis, the molecular weight of the mutant LT subunits were presumed to be identical to those of wild-type LT. These results suggest that mutant LTs consisting of A and B subunits retain the AB₂ conformation similar to wild-type LT.

The ability of mutant LTs to induce morphological changes in cultured Chinese hamster ovary-K1(CHO-K1) cells(ATCC, USA) was tested. The morphological changes in the CHO-K1 cells were used to detect the toxic activity of mutant LTs(see: Grant, C.C.R. et al., Infect. Immun., 62:4270-4278(1994)). As little as 100ng/ml of LT induced longitudinal growth of approximately 90% of the CHO-K1 cells, a response previously shown to be dependent upon adenylate cyclase-induced increases in cAMP(see: Guerrant, R.L. et al., Infect. Immun., 10:320-327(1974)). However, the cells treated with each of the mutant LT at the level

of 10µg/ml showed no morphological changes of the CHO-K1 cells.

ADP-ribosyltransferase activity was determined as the ability to catalyze the transfer of labeled ADP-ribose from [adenylate-³²P]NAD to the 41kDa G protein in CHO-K1 membrane(see: Locht, C. et al., Infect. Immun., 55:2546-2553(1987)). In general, A1 subunit of LT is known to catalyze ADP-ribosylation of the membrane-bound substrate G proteins. When membrane proteins from CHO-K1 cells were incubated with wild-type LT in the presence of [adenylate-³²P]NAD, it specifically ADP-ribosylated the Mr 41,000 proteins, which correspond to the α subunits of the GTP binding Gs protein. In contrast, no ADP-ribosylation of this protein was detected in reaction mixtures incubated with the same amounts of LTS63Y or LTΔ110/112. This result was identical to that of the negative control treated without toxins. Therefore, the substitution of Tyr⁶³ for Ser⁶³ or deletion of Glu¹¹⁰ and Glu¹¹² in A1 subunit appeared to cause changes in structural integrity of NAD binding crevice that may be important for enzymatic activity of LT.

In addition, the levels of cAMP were determined in CHO cells treated with CT, LT, or mutant LTs. The addition of CT or LT caused about 10-fold higher levels of cAMP production than that of untreated cultures. On the other hand, changes in cAMP levels in LTS63Y- or LTΔ110/112-treated cells were barely detectable. These data showed that the presence of A subunit of wild-type LT(accurately LTA1 subunit) is necessary for an increase in the intracellular cAMP concentration and the mutant derivatives, LTS63Y and LTΔ110/112, devoid of enzymatic activity, are unable to form cAMP.

The enterotoxicity experiments of mutant LTs examined using a mouse ileal loop test strongly indicate that the mutant LTs possess negligible enterotoxicity in vivo.

In the immunogenic ability of mutant LTs, the mice immunized with LTS63Y or LTΔ110/112 contained high and

comparable levels of anti-LT antibodies in sera and fecal extracts compared with those immunized with wild-type LT. Moreover, both of the intragastric and intranasal immunizations using mutant LTs could be an effective method for inducing antibody responses of vaccination.

The ability of mutant LTs to act as a mucosal adjuvant was assessed by intragastric immunization in mice. LT/110/112 was effective as a mucosal adjuvant on intragastric immunization by inducing high levels of mucosal and systemic antibody responses to the coadministered antigens such as *H. pylori* whole cell lysate or urease. The ability of mutant LTs to function as a mucosal adjuvant was also assessed by intranasal immunization in mice. Intranasal administration of LTS63Y demonstrated the sensitiveness in inducing mucosal immunogenicity and adjuvanticity. Mice immunized intranasally by coadministration of urease antigen and LTS63Y showed strong mucosal and systemic anti-urease responses including urease-specific secretory IgA, serum IgG and IgA antibodies.

The present invention is further illustrated in the following examples, which should not be taken to limit the scope of the invention.

Example 1: Expression and Purification of mutant LTs

Example 1-1: Plasmid construction and mutagenesis

A 1.5Kb *Bam*HI DNA fragment including LT gene from enterotoxigenic *E. coli* K88ac strain of porcine origin was cloned into pBluescript KS(-) vector(Stratagene, USA). The resulting vector, designated as pBlueKS-/rLT, was used for site-directed mutagenesis.

Site-directed mutagenesis was performed on single-stranded DNA prepared from *E. coli* CJ236 transformed with pBlueKS-/rLT according to the method of MutanK kit(Takara

Biomedicals, Japan). The sequence of oligonucleotides used for the substitution and deletion of amino acids were 5'-ATATGATGACGGATATGTTTCCACTTACCTTAGTTTGAGAAGTGCTCACTTG-3' (SEQ ID NO:1) and 5'-AGGCGTATACAGCCCTCACCCATATCAGGTTTCTGCGTTAGG
5 TGG AATACCAT-3' (SEQ ID NO:2), respectively. As a result, serine residue at position 63 was substituted with tyrosine and glutamic acid residues at positions 110 and 112 were deleted, respectively.

These residues are in proposed ADP-ribosyltransferase
10 active center of LT and their substitutions or deletions have been shown to inactivate ADP-ribosyltransferase activity and enterotoxicity (see: Domenighini, M. et al., Mol. Microbiol., 14:41-50(1994)).

Amino acids at positions 58 to 72 are shown to be
15 folded in a β -strand followed by α -helix, which form the NAD-binding site and amino acids Arg⁷, His⁴⁴, Ser⁶¹ Glu¹¹⁰ and Glu¹¹² have been shown to be important for enzymatic activity. Up to date, the modified residues of the LTA subunit are Arg⁷(to Lys), Ser⁶³(to Lys), Glu¹¹⁰(to Asp),
20 Glu¹¹²(to Asp or Lys) or Ala⁷²(to Arg) (see: Lobet, Y. et al., Infect. Immun., 59:2870-2879(1991); Fontana, M.R. et al., Infect. Immun., 63:2356-2360(1995); Di Tommaso, A. et al., infect. Immun., 64:974-979(1996); Douce, G. et al., Infect. Immun., 63:2821-2828(1997); Marchetti, M.M. et al., Vaccine,
25 16:33-37(1998); Tsuji, T. et al., FEBS Letters, 292:319-321(1991); Lycke, N. et al., Eur. J. Immunol., 22:2277-2281(1992); Verweij, W.R. et al., Vaccine, 16:2069-2076(1998); Giuliani, M.M. et al., J. Exp. Med., 187:1123-1132(1998)).

30 The substitution of Ser⁶³, the essential amino acid for NAD-binding and catalytic activity of LT, with Tyr residue having a bulky side chain of phenolic ring was expected to efficiently block NAD-binding in slightly modified LT structure. Deletion of Glu¹¹⁰ and Glu¹¹²,
35 which are located at the putative ADP-ribosyltransferase active center was also expected to completely eliminate enzymatic activity of LT.

The changes of DNA sequences were confirmed using Sequenase Version 2.0 sequencing kit (Amersham Life Science, USA) and each of mutants thus prepared was designated as 'pBlueKS-/LTS63Y' and 'pBlueKS-/LTΔ110/112', respectively.

Example 1-2: Expression and purification of the recombinant mutant LTs

pBluescript KS(-) vectors containing the mutant LT gene which comprises the 160bp 5'-noncoding region, 1.2kb coding region and 197bp 3'-noncoding region, pBlueKS-/LTS63Y and pBlueKS-/LTΔ110/112, were transformed into *E. coli* Top 10F' (Invitrogen, USA). Each of the transformants thus prepared was designated as '*Escherichia coli* Top 10F'-pBlueKS-/LTS63Y' and '*Escherichia coli* Top 10F'-pBlueKS-/LTΔ110/112' and deposited with the Korean Collection for Type Cultures (KCTC) located at KRIBB #52, Oun-dong, Yusong-gu, Taejon 305-333, Republic of Korea, an international depository authority as accession Nos. KCTC 0648BP and KCTC 0649BP, respectively.

E. coli Top 10F' transformed with either LTS63Y or LTΔ110/112 was grown in LB broth containing 100 µg/ml of ampicillin and the mutant LTs were purified from the cultures. The cells were harvested by centrifugation, resuspended in TEAN buffer (50mM Tris-HCl, pH 7.5, 0.2M NaCl, 1mM EDTA and 3mM NaN₃), and lysed with a microfluidizer (Microfluidics Corporation, USA). The lysates were clarified by centrifugation and then filtered using 0.45µm membrane (Micro Filtration Systems, Japan) prior to chromatography on an immobilized D-galactose column (Pierce, USA) (see: Uesaka, Y. et al., Microb. Pathog. 16:71-76(1974)). Bound proteins were eluted with 0.3M galactose in TEAN buffer. Holotoxin (AB₅) was separated from the free B-subunit pentamer by size exclusion chromatography using FPLC Superdex 200 column (Pharmacia, Sweden).

The homogeneity of LTS63Y and LTΔ110/112 was confirmed by SDS-polyacrylamide gel electrophoresis (see:

Figure 1). In Figure 1, lanes 1 and 2 represent wild-type LTs; lanes 3 and 4, LTS63Ys; and, lanes 5 and 6, LTΔ110/112s, respectively, and the arrow 1 is a position of LT holotoxins and LTB subunit pentamers; arrow 2, LTA subunit; and, arrow 3, LTB subunit monomer. Each lane received 10μg of the proteins and samples in lanes 2, 4 and 6 were heated to 95°C for 5min in the presence of β-mercaptoethanol, while samples in lanes 1, 3 and 5 were loaded without denaturation by heating and adding β-mercaptoethanol. When the purified mutant LTs were analyzed without denaturation, two protein bands appeared: one band with the size of 70-100kDa corresponding to the holotoxin and LTB pentamers; and, the other band with the size of about 30kDa corresponding to the LTA subunit. When the purified mutant LTs were boiled for 5min with β-mercaptoethanol, the holotoxins were dissociated into two bands of about 30 and 11kDa, corresponding to the A and B subunits of LT, respectively. Since the mobilities of mutant LTs were identical to those of the wild-type LT, the molecular weight of the mutant LT subunits were presumed to be identical to those of wild-type LT.

These results suggest that the innate structure of the A subunit associated with pentameric B subunits of LT is not affected by substitution of tyrosine for Ser⁶³ or deletion of Glu¹¹⁰ and Glu¹¹² residues on NAD-binding pocket. Moreover, it was demonstrated that the binding ability of the B subunit of mutant LTs to G_{M1} ganglioside was similar to that of the normal B subunit using a G_{M1}-ELISA, and mutant LTs were reacted with anti-LT antibody in Western blot analysis. These results imply that mutant LTs retain the AB₅ conformation similar to wild-type LT.

Example 2: Enzymatic and Biologic Characterization of mutant LTs

Example 2-1: Cell elongation assay

The ability of mutant LTs to induce morphological changes in cultured Chinese hamster ovary-K1 (CHO-K1) cells (ATCC, USA) was tested as described previously (see: Guerrant, R.L. et al., Infect. Immun., 10:320-327 (1974); Grant, C.C.R. et al., Infect. Immun., 62:4270-4278 (1994)). CHO-K1 cells were incubated for 24hr as monolayer cultures in minimal essential medium alpha (MEM- α) (Gibco-BRL, USA) supplemented with 10% fetal bovine serum (FBS) in humidified and 5% CO₂ atmosphere at 37°C. The cells were washed once with Hanks's balanced salt solution (HBSS) (Sigma, USA) and then incubated with 0.1% trypsin for 5min. After centrifugation, they were washed once, and then resuspended in the growth medium. To each well of a 48-well tissue culture plate, the same numbers of CHO-K1 cells (10⁴ in 200 μ l volume per well) were allowed to adhere for 4hr prior to the addition of the toxin dilutions and then incubated in humidified and 5% CO₂ atmosphere at 37°C for 24hr. The cells were then washed with phosphate-buffered saline (PBS), fixed with methanol, and stained with 0.04% Trypan Blue Solution (Gibco-BRL, USA). After staining, the cells were washed, air dried, and analyzed for morphological changes by light microscopy.

The morphological changes in the CHO-K1 cells were used to detect the toxic activity of mutant LTs (see: Grant, C.C.R. et al., Infect. Immun., 62:4270-4278 (1994)). As little as 100ng/ml of wild-type LT induced longitudinal growth of approximately 90% of the CHO-K1 cells, a response previously shown to be dependent upon adenylate cyclase-induced increases in cAMP (see: Guerrant, R.L. et al., Infect. Immun., 10:320-327 (1974)). However, the cells treated with mutant LTs at the level of 10 μ g/ml showed no morphological changes of the CHO-K1 cells (see: Figure 2 and Table 1). In Figure 2, A shows toxin-untreated CHO-K1 cells; B, CHO-K1 cells treated with 100ng/ml of wild-type LT; C, CHO-K1 cells treated with 10 μ g/ml of LTS63Y; and, D, CHO-K1 cells treated with 10 μ g/ml of LT/110/112, respectively.

Table 1. Comparison of biologic and enzymatic activities of wild-type LT, LTS63Y and LTΔ110/112

Toxin assessed	Cell elongation ^a	Ileal loop test ^b
PBS	10%<	negative
Wild-type LT	90%> at 100ng	positive at 100ng
LTS63Y	10%< at 10μg	negative at 100μg
LTΔ110/112	10%< at 10μg	negative at 100μg

a: 10⁴ of CHO-K1 cells were cultured with 100ng of wild-type LT or 10μg of each mutant LT for 24hr and a positive toxin effect in the CHO-K1 cells was defined as elongation of >20% of the cells according to published criteria(see: Guerrant, R.L. et al., Infect. Immun. 10:320-327 (1974))

b: The enterotoxicity of mutant LTs was examined using on ileal loop test, where mice were anesthetized, and 100μl of PBS containing 100ng of wild-type LT or 100μg of each mutant LT was injected into an ileal loop. Loops were examined 18hr later and the ratio of fluid to length was defined as positive when the ratio was >40μl/cm(see: Fujita, K. et al., J. Infect. Dis. 125: 647-655 (1972))

Example 2-2: ADP-ribosyltransferase activity test

For the preparation of crude membranes, CHO-K1 cells were maintained in monolayer culture by serial passage in MEM-α medium supplement with 10% FBS(see: Loch C. et al., Infect. Immun., 55:2546-2553(1987)). The cells were detached from the flask, washed once in PBS(pH 7.2) and then lysed in a homogenizer (Weaton, USA). The supernatant from these lysates was collected following centrifugation at 1,000xg for 20 min and further centrifuged at 18,000xg for 7 min to obtain microsomal or membrane pellets. The washed membrane pellet was resuspended in 50mM Tris-HCl(pH8.0) at a concentration of 1mg of protein per ml and stored at -70°C until use.

ADP-ribosyltransferase activity was determined as the ability to catalyze the transfer of labeled ADP-ribose from [adenylate-³²P]NAD to the 41kDa G protein in CHO-K1 membrane(see: Loch C. et al., Infect. Immun., 55:2546-2553(1987)). Reaction mixtures (100μl) containing 32μM [adenylate-³²P]NAD(2μCi) (NEN, USA), 50 mM Tris-HCl(pH 8.0)

containing 10mM thymidine, 100mM ATP, 20mM DTT, 100μM GTP, 50μg of CHO-K1 membrane proteins, and 10μg of wild-type or mutant LTs were incubated at 37°C for 30min. Reactions were terminated by the addition of 1ml of ice-cold 50mM Tris-HCl(pH 8.0) and the membranes were sedimented by centrifugation(15,000xg, 7min) at 4°C. The membrane pellet was resuspended in ice-cold Tris-HCl(pH 8.0) and sedimented once more by centrifugation before being solubilized in 50μl of electrophoresis sample buffer(67mM Tris-HCl, pH 6.8, 2% SDS, 0.03% bromophenol blue, and 10% glycerol) containing 5% β-mercaptoethanol. The samples were heated to 95°C for 5min and then analyzed by SDS-PAGE and autoradiography.

In general, the A1 subunit of LT is capable of binding NAD and catalyzing the ADP-ribosylation of membrane-bound Gs, a GTP-binding regulatory protein associated with adenylate cyclase(see: Spangler, B.D., Microbiol. Rev., 56:622-647(1992)). The consequence is a sharp increase in cAMP production resulting in excessive accumulation of salts and water in the intestinal lumen(see: Field, M. et al., N. Engl. J. Med., 322:800-806(1989)). The A subunit of LT is known to catalyze ADP-ribosylation of the membrane-bound substrate G proteins.

Figure 3 shows ADP-ribosyltransferase activity of LT, LTS63Y and LTΔ110/112 analyzed by SDS-PAGE in a 12.5% gel followed by autoradiography. In Figure 3, lane 1 represents a reaction mixture incubated without toxins; lane 2, with 10μg of wild-type LT; lane 3, with 10μg of LTS63Y; and, lane 4, with 10μg of LTΔ110/112, respectively, and the arrow denotes the position of the Mr-41,000 band corresponding to the Gs protein.

As shown in Figure 3, when 50μg of membrane proteins from CHO-K1 cells were incubated with wild-type LT in the presence of [adenylate-³²P]NAD, it specifically ADP-ribosylated the Mr-41,000 proteins, which correspond to the α subunits of the GTP binding Gs proteins. In contrast, no ADP-ribosylation of this protein was detected in reaction

mixtures incubated with the same amounts of LTS63Y or LTΔ110/112. This result was identical to that of the negative control treated without toxins in lane 1. Therefore, the substitution of Tyr⁶³ for Ser⁶³ or deletion of Glu¹¹⁰ and Glu¹¹² in A subunit did cause changes in structural integrity of NAD binding crevice that may be important for enzymatic activity of LT.

Example 2-3: Measurement of intracellular cAMP accumulation

CHO cells(ATCC, USA) were maintained in MEM-α medium supplemented with 10% FBS in a 24-well plate at a concentration of 5x10⁴ cells per well, grown to near confluency, and incubated in MEM-α containing FBS and 1mM 3-isobutyl-1-methylxanthine (IBMX) for 30min prior to addition of toxins(see: Grant, C.C.R. et al., Infect. Immun., 62:4270-4278(1994)). Either cholera toxin(CT), cholera toxin B subunit(CTB), trypsin-activated wild-type LT, LTS63Y, or LTΔ110/112 was added to each well and the plates were incubated for 18h. The cells were washed three times with PBS and intracellular cAMP was extracted by adding 200μl of 50mM HCl to each well and placing the plates in -70°C deep freezer for 20min. cAMP was measured with a Biotrak cAMP enzyme immuno-assay(EIA) system(Amersham Life Science, USA) according to the manufacturer's instructions.

As a result, the levels of cAMP were determined in CHO cells treated with CT, CTB, LT, LTS63Y, or LTΔ110/112(see: Figure 4). As shown in Figure 4, the addition of CT or LT to reach a concentration of 50ng/ml caused about 10-fold higher levels of cAMP production than those of untreated cultures. On the other hand, cAMP formation in cultures treated with CTB, LTS63Y or LTΔ110/112 was undetectable even at a concentration as high as 5μg/ml. In Figure 4, 'S' and 'D' denote LTS63Y and LTΔ110/112, respectively, and the gray bars represent treatments of 500ng of CT or LT and 5μg of CTB, S or D; and, black bars,

50ng of CT or LT and 500ng of CTB, S or D. Results are shown as mean titers and error bars indicate standard deviations from the mean.

These data showed that the presence of wild-type LTA subunit (accurately LTA1 subunit) is necessary for an increase in the intracellular cAMP concentration and the mutant derivatives, LTS63Y and LTΔ110/112, devoid of enzymatic activity, are unable to form cAMP.

10 Example 2-4: Assessment of toxicity using mouse ileal loops

The enterotoxicity of mutant LTs was examined using a mouse ileal loops test (see: Yamamoto, S. et al., J. Exp. Med., 185:1203-1210(1997)). Groups of mice were anesthetized, and different doses of each toxin were injected into ileal loops (LT, 100ng or 1μg per mouse; and, mLT, 10μg or 100μg per mouse) of individual mice. The mice were sacrificed 18hr after the injection, and the fluid content of the ileal loops was determined; values of more than 40μl/cm were considered positive (indicative of toxicity).

One hundred nanogram of wild-type LT induced significant fluid accumulation in small intestine, while no fluid accumulation was observed in the loop treated with thousand-fold higher levels (100μg) of mutant LTs (see: Table 1). These data strongly indicate that the mutant LTs possess negligible enterotoxicity in vivo.

Example 3: Immunological Characterization

Example 3-1: Mucosal immunogenicities of mLTs

Six-week-old female Balb/c mice were purchased from Charles River (Japan). The mucosal immunogenicities of LTS63Y and LTΔ110/112 were tested via two immunization routes. Groups of mice were immunized intragastrically with 25μg of LTS63Y or LTΔ110/112 four times on days 0, 7,

14 and 21 or intranasally with 2µg of LTS63Y or LTΔ110/112 on days 0, 7 and 14(see: Takahashi, I. et al., J Infect. Dis., 173:627-635(1996)). The control groups received PBS alone. The serum and fecal antibody titers to LT were
5 determined using samples prepared on day 7 following the last immunization(see: Figure 5). Figure 5 shows anti-LT secretory IgA, serum IgG and IgA antibody responses on intragastric(white bar) or intranasal(black bar) immunization, where 1 represents PBS treatment; 2, wild-
10 type LT treatment; 3, LTS63Y treatment; 4, LTΔ110/112 treatment.

As shown in Figure 5, the mice immunized with LTS63Y or LTΔ110/112 contained high and comparable levels of anti-LT antibodies in sera and fecal extracts compared with
15 those immunized with wild-type LT. The LTS63Y was slightly more immunogenic than LTΔ110/112 on both intragastric and intranasal administration. On the other hand, titers of anti-LT in the serum or fecal extracts of mice intranasally immunized with wild-type or mutant LTs were slightly higher
20 than those observed in mice intragastrically administered. Intranasal immunization offers several advantages compared with other immunization route: lower doses of proteins are required to induce antibody responses, which means lower cost for vaccine production(see: Yamamoto, S. et al., Proc.
25 Natl. Acad. Sci., USA, 94:5267-5272(1997)). When administered intranasally, only 6% of the quantity of mutant LT used in intragastric immunization was required to elicit slightly higher levels of secretory IgA responses and this dose also effectively induced systemic IgG and IgA
30 antibody responses. Thus, intranasal immunization using mutant LT could be an effective method for vaccination in humans and animals.

Example 3-2: Mucosal adjuvantivity of mutant LTs

35 To test a mucosal adjuvantivity, mice were immunized either intragastrically by 125µg of *H. pylori* urease

together with 25µg of LTS63Y or LTΔ110/112 on days 0, 7, 14 and 21 or intranasally by 20µg of the same antigen together with 2µg of LTS63Y or LTΔ110/112 as an adjuvant on days 0, 7 and 14. Fecal extracts and serum samples were collected on day 7 following the last immunization and the appearance of either mucosal or systemic antibody responses was monitored using ELISA.

LT- and urease-specific antibodies were measured with a G_{M1} capture enzyme-linked immunosorbent assay (G_{M1}-ELISA) and direct ELISA, respectively, as described previously (see: Spiegel, S. J. Cell. Biochem., 42:143-152(1990); Douce, G. et al., Infect. Immun., 65:2821-2828(1997)). Plates were coated with 150ng of G_{M1} (Sigma, USA) per well of a 96-well EIA/RIA plate (Costar, USA) for a G_{M1}-capture ELISA, and then incubated at 37°C for 1hr. Plates were washed three times with PBS containing 0.05% Tween 20 ("PBST") and blocked with 2.5% skim milk (Difco, USA) in PBST at 37°C for 1hr. After washing with PBST three times, 100ng of wild-type LT was added into wells and plates were incubated for 1hr at 37°C and washed three times with PBST. In case of a direct ELISA, plates were coated with 1µg of urease per well incubated for 1hr at 37°C with horseradish peroxidase (HRP)-conjugated anti-mouse antibodies specific for mouse immunoglobulin G (IgG) (1:5000), IgA (1:2000) (KPL, USA) or IgG1, IgG2a or IgG2b (1:2000) (Biosource, USA). After washing six times with PBST, bound antibody was visualized by addition of 3,3',5,5'-tetramethylbenzidine (TMB). The absorbance at 450 nm was determined and ELISA titers were recorded as the highest dilution of serum which gave an absorbance value above the level measured in preimmune samples.

Mucosal adjuvanticity of LTS63Y and LTΔ110/112 by intragastric immunization

The ability of mutant LTs to act as a mucosal adjuvant was assessed by intragastric immunization in

mice(see: Figure 6: 1, PBS treatment; 2, 125µg urease treatment; 3, 125µg urease and 25µg LT treatment; 4, 125µg urease and 25µg LTS63Y treatment; 5, 125µg urease and 25µg LTΔ110/112 treatment).

5 As shown in Figure 6, mice immunized intragastrically with *H. pylori* urease alone showed no significant levels of antibodies to the antigen. Mice immunized by coadministration of urease and LTΔ110/112 produced high levels of urease antibody responses comparable to those
10 immunized with wild-type LT, while mice immunized by coadministration of the antigen and LTS63Y showed no significant sero-conversion. Altering the dose of LTΔ110/112 to 10 or 125µg did not cause any change in the immune response to urease. LTS63Y did not show any
15 significant adjuvanticity to the urease, even when 125µg was coadministered with the urease.

To test the adjuvanticity of LTΔ110/112 with other antigens, whole cell lysate of *H. pylori* was used as an antigen and it was observed that LTΔ110/112 also induced
20 antibody responses to whole cell lysate. These data suggest that LTΔ110/112 effectively functions as a mucosal adjuvant on intragastric immunization by inducing strong mucosal and systemic antibody responses to coadministered antigens such as *H. pylori* whole cell lysate or urease.

25 To further assess the immunologic response induced by LTΔ110/112 following intragastric immunization, IgG subclass responses were determined by ELISA(see: Figure 8A: 1, PBS treatment; 2, 125µg urease treatment; 3, 125µg urease and 25µg LT treatment; 4, 125µg urease and 25µg
30 LTS63Y treatment; 5, 125µg urease and 25µg LTΔ110/112 treatment).

As shown in Figure 8A, urease antibody responses enhanced by LTΔ110/112 were largely restricted to IgG1(gray bars), rather than IgG2a(white bars) or
35 IgG2b(black bars) subclass antibody in sera, and similar antibody patterns were observed using wild-type LT as an adjuvant.

Generally, CT elicits adjuvant responses by inducing antigen-specific CD4+ T cells secreting interleukin 4 (IL-4), IL-5, IL-6 and IL-10 that correlated directly with serum IgG1 and IgG2b subclass responses in mice orally immunized with protein Ag and CT as adjuvant (see: Marinaro, M. et al., J. Immunol., 155:4621-4629 (1995)). It was reported that mutant CT(S61F), despite lack of ADP-ribosyltransferase activity with resultant cAMP induction, elicits serum IgG1 and IgG2b subclass Ab responses when administered intranasally (see: Yamamoto, S. et al., Proc. Natl. Acad. Sci., USA, 94:5267-5272 (1997) or subcutaneously (see: Yamamoto, S. et al., J. Exp. Med., 185:1203-1210 (1997)). On the other hand, oral immunization with LT promotes IgG1, IgG2a and IgG2b, which are supported by a mixed CD4+ Th1- and Th2-type responses associated with IFN- γ , IL-4, IL-5, IL-6 and IL-10 production (see: Takahashi, I. et al., J. Infect. Dis., 173:627-635 (1996)). In the results of present invention, intragastric administration of LT Δ 110/112 or wild-type LT as an adjuvant induced predominant IgG1 Ab responses as shown in Figure 8A. This result is not consistent with the typical IgG subclass responses induced by wild-type LT and rather resembles the responses induced by CT activating CD4+ Th2-type cells (see: Marinaro, M. et al., J. Immunol., 155:4621-4629 (1995)). In contrast, LTS63Y induced IgG1, IgG2a and IgG2b antibody responses to *H. pylori* urease on intranasal immunization. The similar result is also observed by wild-type LT eliciting IgG1, IgG2a and IgG2b subclass responses, which are supported by a mixed CD4+ Th1- and Th2-type response (see: Takahashi, I. et al., J. Infect. Dis., 173:627-635 (1996)). Therefore, the mutant LTs of this invention, LTS63Y and LT Δ 110/112, induced distinct IgG subclass responses, depending on immunization routes.

Mucosal adjuvanticity of LTS63Y and LT Δ 110/112 by intranasal immunization

The ability of mutant LTs to function as a mucosal adjuvant was also assessed by intranasal immunization in mice. Intranasal administration of wild-type or mutant LTs demonstrated the sensitiveness in inducing mucosal immunogenicity and adjuvanticity(see: Figure 7: 1, PBS treatment; 2, 20µg urease treatment; 3, 20µg urease and 2µg wild-type LT treatment; 4, 20µg urease and 2µg LTS63Y treatment; 5, 20µg urease and 2µg LTΔ110/112 treatment).

Mice immunized intranasally by coadministration of urease antigen and LTS63Y showed high levels of mucosal and systemic anti-urease responses including urease-specific secretory IgA, serum IgG and IgA antibodies, which were equivalent to the responses observed when wild-type LT was used as an adjuvant. However, mice immunized by coadministration of urease and LTΔ110/112 showed lower level of antibodies to urease, similar to those levels induced by urease alone. When 0.2µg of LTS63Y was used, antibody responses to urease in both fecal extracts and sera were lower by a factor of approximately 10, but when 6µg of LTS63Y was used, no increase in antibody responses to urease was induced.

In addition, as shown in Figure 8B, LTS63Y induced IgG1(gray bars), IgG2a(black bars) and IgG2b(white bars) subclass antibody responses to *H. pylori* urease, and these results were quite different from those IgG subclass responses(predominant IgG1) resulted from the intragastric immunization with the mutant LTΔ110/112(see: Figure 8B: 1, PBS treatment; 2, 20µg urease treatment; 3, 20µg urease and 2µg LT treatment; 4, 20µg urease and 2µg LTS63Y treatment; 5, 20µg urease and 2µg LTΔ110/112 treatment). Therefore, the mutant LTs of this invention, LTS63Y and LTΔ110/112 induced distinct IgG subclass responses, depending on immunization routes.

As described above, the mutant LTs of this invention have shown different abilities to act as mucosal adjuvant according to the route of administration. This suggests that different mutant forms of LT may require different

immunization routes for adequate adjuvant activity, and that specific immunization route may elicit specific mechanisms of up-regulation of immune responses, independent of cAMP levels. Thus, selection of the route of immunization may be critical for determining the mucosal adjuvant activity of mutant LTs. Mucosal vaccines delivered into the nasal tract provide several advantages. For example, lower doses of antigen and adjuvant are required to induce effective antibody responses when compared to intragastric immunization, which can decrease the cost of vaccination.

As clearly illustrated and demonstrated as above, the present invention provides detoxified and immunologically active proteins (mutant LTs). The mutant LTs were expressed from recombinant expression vectors, pBlueKS-/LTS63Y and pBlueKS-/LTΔ110/112 that contain mutated DNA sequences encoding amino acids in the ADP-ribosyltransferase active center. In contrast to wild-type LT, both of the LTS63Y and LTΔ110/112 did not induce any toxic activities. Both of the mutants elicited high and comparable levels of anti-LT antibodies when delivered either intragastrically or intranasally, inducing systemic and local responses in serum and fecal extracts. Thus, they might be useful for the development of a novel diarrheal vaccine in human and animals. In addition, the antibody production ability using LTS63Y and LTΔ110/112 as adjuvants against *H. pylori* urease may be effective for prevention and treatment of various diseases. The adjuvant activity of these mutants might be very useful to develop an effective mucosal vaccine component.


BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT
OF MICROORGANISMS FOR THE PURPOSE OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT

issued pursuant to Rule 7.1

TO: Mogen Biotechnology Research Institute
 #341, Pujung-ri, Kausung myun, Yongin si, Kyonggi-do 410-010,
 Republic of Korea

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <i>Escherichia coli</i> Top10F'-pBlueKS ⁺ /LTS63Y	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: KCTC 0648BP
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by: <input checked="" type="checkbox"/> a scientific description <input type="checkbox"/> a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on Jul 27 1999 .	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on _____ and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on _____	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Korean Collection for Type Cultures Address: Korea Research Institute of Bioscience and Biotechnology (KRIBB) #52, Oun-dong, Yusong-ku, Taejon 305-333, Republic of Korea	Signature(s) of person(s) having the power to represent the International Depositary Authority of authorized official(s):  BAE, Kyung Sook, Director Date: Aug 02 1999


BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF THE DEPOSIT
OF MICROORGANISMS FOR THE PURPOSE OF PATENT PROCEDURE

INTERNATIONAL FORM

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT

issued pursuant to Rule 7.1

TO: Mogen Biotechnology Research Institute
#341, Pajung-ri, Koosung-myun, Yongin-si, Kyonggi-do 449-910,
Republic of Korea

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: <i>Escherichia coli</i> Top10F'-pBlueKS ⁺ /LT 110/112 .	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: KCTC 0649BP
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
The microorganism identified under I above was accompanied by: [x] a scientific description [] a proposed taxonomic designation (Mark with a cross where applicable)	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I above, which was received by it on Jul 27 1999 .	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: Korean Collection for Type Cultures Address: Korea Research Institute of Bioscience and Biotechnology (KRIBB) #52, Oun-dong, Yusong-ku, Taejon 305-333, Republic of Korea	Signature(s) of person(s) having the power to represent the International Depositary Authority of authorized official(s):  BAE, Kyung Sook, Director Date: Aug 02 1999

WHAT IS CLAIMED IS:

1. A detoxified and immunologically active protein
5 having an amino acid sequence of heat-labile enterotoxin of *E. coli*, in which position 63 or positions 110 and 112 is mutated in a site-directed manner.
2. A detoxified and immunologically active protein
10 having an amino acid sequence of heat-labile enterotoxin of *E. coli*(SEQ ID NO:3), in which serine residue at position 63 is substituted with tyrosine.
3. A DNA sequence(SEQ ID NO:4) encoding the
15 detoxified and immunologically active protein of claim 2.
4. A recombinant expression vector pBlueKS-/LTS63Y which comprises the DNA of claim 3.
- 20 5. *Escherichia coli* Top10F'-pBlueKS-/LTS63Y(KCTC 0648BP) transformed with the recombinant expression vector pBlueKS-/LTS63Y of claim 4.
6. A detoxified and immunologically active protein
25 having an amino acid sequence of heat-labile enterotoxin of *E. coli*(SEQ ID NO:5), in which glutamic acid residues at positions 110 and 112 are deleted.
7. A DNA sequence(SEQ ID NO:6) encoding the
30 detoxified and immunologically active protein of claim 6.
8. A recombinant expression vector pBlueKS-/LT Δ 110/112 which comprises the DNA of claim 7.
- 35 9. *Escherichia coli* Top10F'-pBlueKS-/LT Δ 110/112(KCTC 0649BP) transformed with the recombinant expression vector pBlueKS-/LT Δ 110/112 of claim 8.

10. A process for preparing the detoxified and immunologically active protein(mutant LT) of claim 1 which comprises the steps of culturing a recombinant
5 microorganism transformed with an expression vector comprising a DNA encoding the mutant LT and isolating the recombinant mutant LT from the culture.

11. The process for preparing the detoxified and
10 immunologically active protein of claim 10, wherein the recombinant microorganism is *Escherichia coli* Top10F'-pBlueKS-/LTS63Y(KCTC 0648BP) or *Escherichia coli* Top10F'-pBlueKS-/LT/110/112(KCTC 0649BP).

12. A diarrheal vaccine comprising an active
15 ingredient of the detoxified and immunologically active protein of claim 1 and pharmaceutically acceptable carrier.

13. A mucosal adjuvant comprising an active
20 ingredient of the detoxified and immunologically active protein of claim 1.

1/9




Fig. 1

2/9




Fig. 2

3/9




Fig. 3

4/9




Fig. 4

5/9




Fig. 5

6/9




Fig. 6

7/9




Fig. 7

8/9




Fig. 8A

9/9




Fig. 8B

SEQUENCE LISTING

<110> MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE et al.

5

<120> NOVEL DETOXIFIED MUTANTS OF *Escherichia coli* HEAT-LABILE ENTEROTOXIN

<160> 6

10

<170> KOPATIN 1.5

<210> 1

<211> 52

15

<212> DNA

<213> Artificial Sequence

<220>

<223> single-stranded nucleotide

20

<400> 1

atatgatgac ggatatgttt ccacttacct tagtttgaga agtgctcact tg 52

25

<210> 2

<211> 53

<212> DNA

<213> Artificial Sequence

30

<220>

<223> single-stranded oligonucleotide

<400> 2

aggcgtatac agccctcacc catatcaggt ttctgcgta ggtggaatac cat 53

35

<210> 3

<211> 382
<212> PRT
<213> Escherichia coli

5 <400> 3
Met Lys Asn Ile Thr Phe Ile Phe Phe Ile Leu Leu Ala Ser Pro Leu
1 5 10 15
Tyr Ala Asn Gly Asp Arg Leu Tyr Arg Ala Asp Ser Arg Pro Pro Asp
10 20 25 30
Glu Ile Lys Arg Ser Gly Gly Leu Met Pro Arg Gly His Asn Glu Tyr
35 40 45
15 Phe Asp Arg Gly Thr Gln Met Asn Ile Asn Leu Tyr Asp His Ala Arg
50 55 60
Gly Thr Gln Thr Gly Phe Val Arg Tyr Asp Asp Gly Tyr Val Ser Thr
65 70 75 80
20 Tyr Leu Ser Leu Arg Ser Ala His Leu Ala Gly Gln Ser Ile Leu Ser
85 90 95
Gly Tyr Ser Thr Tyr Tyr Ile Tyr Val Ile Ala Thr Ala Pro Asn Met
25 100 105 110
Phe Asn Val Asn Asp Val Leu Gly Val Tyr Ser Pro His Pro Tyr Glu
115 120 125
30 Gln Glu Val Ser Ala Leu Gly Gly Ile Pro Tyr Ser Gln Ile Tyr Gly
130 135 140
Trp Tyr Arg Val Asn Phe Gly Val Ile Asp Glu Arg Leu His Arg Asn
145 150 155 160
35 Arg Glu Tyr Arg Asp Arg Tyr Tyr Arg Asn Leu Asn Ile Ala Pro Ala
165 170 175

Glu Asp Gly Tyr Arg Leu Ala Gly Phe Pro Pro Asp His Gln Ala Trp
180 185 190

5 Arg Glu Glu Pro Trp Ile His His Ala Pro Gln Gly Cys Gly Asn Ser
195 200 205

Ser Arg Thr Ile Thr Gly Asp Thr Cys Asn Glu Glu Thr Gln Asn Leu
210 215 220

10 Ser Thr Ile Tyr Leu Arg Glu Tyr Gln Ser Lys Val Lys Arg Gln Ile
225 230 235 240

Phe Ser Asp Tyr Gln Ser Glu Val Asp Ile Tyr Asn Arg Ile Arg Asp
15 245 250 255

Glu Leu Met Asn Lys Val Lys Phe Tyr Val Leu Phe Thr Ala Leu Leu
260 265 270

20 Ser Ser Leu Cys Ala His Gly Ala Pro Gln Ser Ile Thr Glu Leu Cys
275 280 285

Ser Glu Tyr His Asn Thr Gln Ile Tyr Thr Ile Asn Asp Lys Ile Leu
290 295 300

25 Ser Tyr Thr Glu Ser Met Ala Gly Lys Arg Glu Met Val Ile Ile Thr
305 310 315 320

Phe Lys Ser Gly Ala Thr Phe Gln Val Glu Val Pro Gly Ser Gln His
30 325 330 335

Ile Asp Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg
340 345 350

35 Ile Thr Tyr Leu Thr Glu Thr Lys Ile Asp Lys Leu Cys Val Trp Asn
355 360 365

Asn Lys Thr Pro Asn Ser Ile Ala Ala Ile Ser Met Glu Asn

370

375

380

5 <210> 4
 <211> 1514
 <212> DNA
 <213> Escherichia coli

10 <400> 4
 ggatccgtgc actctttctt tatcgttca ctacacatt taccctcgca tggatgttt 60
 ataaaaaaca tgattgacat catgttgc ataggttaaa caaaacaagt ggcgttatct 120
 15 ttcccgat tgcttcttg tatgatata aagtttcct cgaatgaaa atataactt 180
 cttttttt attttattag catcgccatt atatgcaat ggcgacagat tataccgtgc 240
 tgactctaga ccccagatg aaataaaacg ttccggaggt cttatgccca gagggcataa 300
 20 tgagtacttc gatagaggaa ctcaaatgaa tattaatctt tatgatcacg cgagaggaac 360
 acaaaccggc ttgtcagat atgatgacgg atatgttcc acttaccta gttigagaag 420
 25 tgctcactta gcaggacagt ctatattac aggatattcc acttactata tatatgtat 480
 agcgacagca ccaaatatgt ttaatgtaa tgatgtatta ggcgtatata gccctcacc 540
 atatgaacag gaggtttctg cgtaggtgg aataccatat tctcagatat atggatggt 600
 30 tcgtgtaat ttggtgtga ttgatgaacg attacatgt aacagggat atagagaccg 660
 gtattacaga aatctgaata tagctccggc agaggatgtg tacagattag caggtttccc 720
 accggatcac caagcttga gagaagaacc ctggattcat catgcaccac aaggttgtg 780
 aaattcatca agaacaatca caggtgatac ttgtaatgag gagaccaga atctgagcac 840

	aatatatctc agggaatatc aatcaaaagt taagaggcag atatttcag actatcagtc	900	
5	agaggttgac atatataaca gaattcggga tgaattatga ataaagtaaa attttatgtt	960	
	ttattacgg cgttactatc ctctctatgt gcacacggag ctctcagtc tattacagaa	1020	
	ctatgttcgg aatatcacia cacacaaata tatacgataa atgacaagat actatcatat	1080	
10	acggaatcga tggcaggcaa aagagaaatg gttatcatta catttaagag cggcgcaaca	1140	
	tttcaggctg aagtcccgga cagtcaacat atagactccc aaaaaaagc cattgaaagg	1200	
	atgaaggaca cattaagaat cacatatctg accgagacca aaattgataa attatgtgta	1260	
15	tggaataata aaacccccaa ttcaattgcg gcaatcagta tggaaaacta gtttgcttta	1320	
	aaagcatgic taatgctagg aacctatata acaactactg tacttatact aatgagcctt	1380	
20	atgctgcatt tgaaggcg gtagaggatg caataccgat ccttaactg taacactata	1440	
	acagcttcca ctacaggga ctgttatagc aaacagaaaa aactaagcta ggctggaggg	1500	
25	gcaagcttgg atcc	1514	
	<210> 5		
	<211> 380		
	<212> PRT		
30	<213> Escherichia coli		
	<400> 5		
	Met Lys Asn Ile Thr Phe Ile Phe Phe Ile Leu Leu Ala Ser Pro Leu		
	1 5 10 15		
35	Tyr Ala Asn Gly Asp Arg Leu Tyr Arg Ala Asp Ser Arg Pro Pro Asp		
	20 25 30		

Glu Ile Lys Arg Ser Gly Gly Leu Met Pro Arg Gly His Asn Glu Tyr
35 40 45

5 Phe Asp Arg Gly Thr Gln Met Asn Ile Asn Leu Tyr Asp His Ala Arg
50 55 60

Gly Thr Gln Thr Gly Phe Val Arg Tyr Asp Asp Gly Tyr Val Ser Thr
65 70 75 80

10 Ser Leu Ser Leu Arg Ser Ala His Leu Ala Gly Gln Ser Ile Leu Ser
85 90 95

Gly Tyr Ser Thr Tyr Tyr Ile Tyr Val Ile Ala Thr Ala Pro Asn Met
15 100 105 110

Phe Asn Val Asn Asp Val Leu Gly Val Tyr Ser Pro His Pro Tyr Gln
115 120 125

20 Val Ser Ala Leu Gly Gly Ile Pro Tyr Ser Gln Ile Tyr Gly Trp Tyr
130 135 140

Arg Val Asn Phe Gly Val Ile Asp Glu Arg Leu His Arg Asn Arg Glu
145 150 155 160

25 Tyr Arg Asp Arg Tyr Tyr Arg Asn Leu Asn Ile Ala Pro Ala Glu Asp
165 170 175

Gly Tyr Arg Leu Ala Gly Phe Pro Pro Asp His Gln Ala Trp Arg Glu
30 180 185 190

Glu Pro Trp Ile His His Ala Pro Gln Gly Cys Gly Asn Ser Ser Arg
195 200 205

35 Thr Ile Thr Gly Asp Thr Cys Asn Glu Glu Thr Gln Asn Leu Ser Thr
210 215 220

Ile Tyr Leu Arg Glu Tyr Gln Ser Lys Val Lys Arg Gln Ile Phe Ser

225 230 235 240

Asp Tyr Gln Ser Glu Val Asp Ile Tyr Asn Arg Ile Arg Asp Glu Leu

5 245 250 255

Met Asn Lys Val Lys Phe Tyr Val Leu Phe Thr Ala Leu Leu Ser Ser

260 265 270

10 Leu Cys Ala His Gly Ala Pro Gln Ser Ile Thr Glu Leu Cys Ser Glu

275 280 285

Tyr His Asn Thr Gln Ile Tyr Thr Ile Asn Asp Lys Ile Leu Ser Tyr

290 295 300

15

Thr Glu Ser Met Ala Gly Lys Arg Glu Met Val Ile Ile Thr Phe Lys

305 310 315 320

Ser Gly Ala Thr Phe Gln Val Glu Val Pro Gly Ser Gln His Ile Asp

20 325 330 335

Ser Gln Lys Lys Ala Ile Glu Arg Met Lys Asp Thr Leu Arg Ile Thr

340 345 350

25 Tyr Leu Thr Glu Thr Lys Ile Asp Lys Leu Cys Val Trp Asn Asn Lys

355 360 365

Thr Pro Asn Ser Ile Ala Ala Ile Ser Met Glu Asn

370 375 380

30

<210> 6

<211> 1508

<212> DNA

35 <213> Escherichia coli

<400> 6

ggatccgtgc actctttctt tatcgcttca ctacacattt taccctcgca tggatgtttt 60

ataaaaaaca tgattgacat catgttgcat atagggttaa caaaacaagt ggcgttatct 120

5 tttccggat tgtcttcttg tatgatatat aagttttcct cgaatgaaaa atataacttt 180

cattttttt attttattag catcgccatt atatgcaaat ggcgacagat tataccgtgc 240

tgactctaga cccccagatg aaataaaacg ttccggaggt cttatgccca gagggcataa 300

10 tgagtacttc gatagaggaa ctcaaatgaa tattaatctt tatgatcagc cgagaggaac 360

acaaaccggc ttgtcagat atgatgacgg atatgtttcc acttctctta gtttgagaag 420

15 tgctcactta gcaggacagt ctatattatc aggatattcc acttactata tatatgttat 480

agcgacagca ccaaatatgt ttaatgttaa tgatgtatta ggcgtatata gccctcacc 540

atatcaggtt tctgcgttag gtggaatacc atattctcag atatatggat ggtatcgtgt 600

20 taattttgtt gtgattgatg aacgattaca tcgtaacagg gaatatagag accggtatta 660

cagaaatctg aatatagctc cggcagagga tggttacaga tttagcaggtt tcccaccgga 720

25 tcaccaagct tggagagaag aaccctggat tcatcatgca ccacaaggtt gtggaaattc 780

atcaagaaca atcacaggtg atacttgtta tgaggagacc cagaatctga gcacaatata 840

tctcagggaa tatcaatcaa aagttaagag gcagatatatt tcagactatc agtcagaggt 900

30 tgacatatat aacagaattc gggatgaatt atgaataaag taaaatttta tgttttatt 960

acggcggttac taccctctct atgtgcacac ggagctcctc agtctattac agaactatgt 1020

35 tcggaatatc acaacacaca aatatatacg ataaatgaca agatactatc atatacggaa 1080

tcgatggcag gcaaaagaga aatgggtatc attacattta agagcggcgc aacatticag 1140

gtcgaagtc cgggcagtca acatatagac tcccaaaaa aagccattga aaggatgaag 1200

gacacattaa gaatcacata tctgaccgag accaaaaattg ataaattatg tgtatggaat 1260

5 aataaaaccc ccaattcaat tgcggcaatc agtatggaaa actagtgtgc tttaaagca 1320

tgtctaagtc taggaaccta tataacaact actgtactta tactaatgag ccttatgctg 1380

10 catttgaata ggcggtagag gatgcaatac cgatccttaa actgtaacac tataacagct 1440

tccactacag ggagctgtta tagcaaacag aaaaaactaa gctaggctgg aggggcaagc 1500

ttggatcc 1508

INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR 99/00555

CLASSIFICATION OF SUBJECT MATTER

IPC⁷: C 12 N 15/31, 15/09, 1/21; A 61 K 39/108 // (C 12 N 1/21, C 12 R 1:19)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC⁷: C 12 N 15/31, 15/09, 1/21; A 61 K 39/108

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, CAS, STN-registry

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0620850 B1 (CHIRON S.P.A.) 3 March 1999 (03.03.99) page 2, lines 17-25; claims 1,3,5,11,19.	1,10,12,13
A	WO 96/06627 A1 (THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND) 7 March 1996 (07.03.96) amended claims 1,4-12,14-17,19,23-25.	1-13
A	WO 98/28005 A1 (SMITHKLINE BEECHAM BIOLOGICALS S.A.) 2 July 1998 (02.07.98) claims 1,2,6,7,9.	1,13

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

„A“ document defining the general state of the art which is not
considered to be of particular relevance„E“ earlier application or patent but published on or after the international
filing date„L“ document which may throw doubts on priority claim(s) or which is
cited to establish the publication date of another citation or other
special reason (as specified)„O“ document referring to an oral disclosure, use, exhibition or other
means„P“ document published prior to the international filing date but later than
the priority date claimed„T“ later document published after the international filing date or priority
date and not in conflict with the application but cited to understand
the principle or theory underlying the invention„X“ document of particular relevance; the claimed invention cannot be
considered novel or cannot be considered to involve an inventive step
when the document is taken alone„Y“ document of particular relevance; the claimed invention cannot be
considered to involve an inventive step when the document is
combined with one or more other such documents, such combination
being obvious to a person skilled in the art

„&“ document member of the same patent family

Date of the actual completion of the international search

17 May 2000 (17.05.2000)

Date of mailing of the international search report

2 August 2000 (02.08.2000)

Name and mailing address of the ISA/AT

Austrian Patent Office
Kohlmarkt 8-10; A-1014 Vienna
Facsimile No. 1/53424/535

Authorized officer

Mosser

Telephone No. 1/53424/437

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR 99/00555

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
EP	A1	620850	26-10-1994	AT E 177145	15-03-1999
EP	B1	620850	03-03-1999	AU A1 33476/93	28-07-1993
				DE C0 69228563	08-04-1999
				DE T2 69228563	29-07-1999
				EP A1 869181	07-10-1998
				ES T3 2127808	01-05-1999
				GR T3 3029556	30-06-1999
				IT A0 913513	31-12-1991
				IT A 1253009	10-07-1995
				JP T2 7506240	13-07-1995
				MX A1 9207685	31-05-1994
				SG A1 48217	17-04-1998
				WO A1 9313202	08-07-1993
WO	A1	9606627	07-03-1996	AU A1 32337/95	22-03-1996
				AU B2 709779	09-09-1999
				BR A 9508633	30-09-1997
				CA AA 2198586	07-03-1996
				CN A 1164191	05-11-1997
				CZ A3 9700562	15-10-1997
				EP A1 777490	11-06-1997
				EP A4 777490	18-11-1998
				FI A0 970799	26-02-1997
				FI A 970799	24-04-1997
				HU A2 77869	28-09-1998
				JP T2 10505059	19-05-1998
				NO A0 970993	04-03-1997
				NO A 970993	25-04-1997
				NZ A 291262	25-02-1999
				PL A1 318930	21-07-1997
				US A 6019982	01-02-2000
				ZA A 9506412	11-03-1996
WO	A1	9828005	02-07-1998	AU A1 57639/98	17-07-1998
				EP A1 948352	13-10-1999
				GB A0 9626864	12-02-1997
				ZA A 9711565	27-08-1998